Bonesupport: Inconclusive study results, but still a compelling case - Redeye

Redeye returns with a more in-depth view of the case changes following the inconclusive study results from the FORTIFY trial. We argue that the longer-term prospects of the case remain relatively intact, as we believe BONESUPPORT will recommence its US launch of CERAMENT G for the trauma indication, after anticipated FDA discussions granting a De Novo application. The inconclusive study results are not a “curtains-down” event, which we soon expect the market to realize.

Länk till analysen i sin helhet: https://www.redeye.se/research/820694/bonesupport-inconclusive-study-results-but-still-a-compelling-case?utm_source=finwire&utm_medium=RSS